Your browser doesn't support javascript.
Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups.
Whitaker, Heather J; Tsang, Ruby S M; Byford, Rachel; Andrews, Nick J; Sherlock, Julian; Sebastian Pillai, Praveen; Williams, John; Button, Elizabeth; Campbell, Helen; Sinnathamby, Mary; Victor, William; Anand, Sneha; Linley, Ezra; Hewson, Jacqueline; DArchangelo, Silvia; Otter, Ashley D; Ellis, Joanna; Hobbs, Richard F D; Howsam, Gary; Zambon, Maria; Ramsay, Mary; Brown, Kevin E; de Lusignan, Simon; Amirthalingam, Gayatri; Lopez Bernal, Jamie.
  • Whitaker HJ; Statistics, Modelling and Economics Department, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK.
  • Tsang RSM; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Byford R; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Andrews NJ; Statistics, Modelling and Economics Department, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ
  • Sherlock J; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Sebastian Pillai P; Virus Reference Laboratory, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK.
  • Williams J; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Button E; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Campbell H; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK.
  • Sinnathamby M; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK.
  • Victor W; Royal College of General Practitioners Research and Surveillance Centre, Euston Square, London, NW1 2FB, UK.
  • Anand S; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Linley E; Vaccine Evaluation Unit, UK Health Security Agency (formerly Public Health England)), Manchester M13 9WL, UK.
  • Hewson J; Diagnostics and Genomics, UK Health Security Agency (formerly Public Health England), Porton Down, Salisbury SP4 0JG, UK.
  • DArchangelo S; Diagnostics and Genomics, UK Health Security Agency (formerly Public Health England), Porton Down, Salisbury SP4 0JG, UK.
  • Otter AD; Diagnostics and Genomics, UK Health Security Agency (formerly Public Health England), Porton Down, Salisbury SP4 0JG, UK.
  • Ellis J; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK; Virus Reference Laboratory, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK.
  • Hobbs RFD; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Howsam G; Royal College of General Practitioners Research and Surveillance Centre, Euston Square, London, NW1 2FB, UK.
  • Zambon M; Virus Reference Laboratory, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK.
  • Ramsay M; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK.
  • Brown KE; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK.
  • de Lusignan S; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK; Royal College of General Practitioners Research and Surveillance Centre, Euston Square, London, NW1 2FB, UK.
  • Amirthalingam G; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK.
  • Lopez Bernal J; Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency (formerly Public Health England), 61 Colindale Avenue, London NW9 5EQ, UK. Electronic address: jamie.lopezbernal2@phe.gov.uk.
J Infect ; 2022 Jan 03.
Article in English | MEDLINE | ID: covidwho-1788130
ABSTRACT
Background COVID-19 vaccines approved in the UK are highly effective in general population cohorts, however, data on effectiveness amongst individuals with clinical conditions that place them at increased risk of severe disease are limited. Methods We used GP electronic health record data, sentinel virology swabbing and antibody testing within a cohort of 712 general practices across England to estimate vaccine antibody response and vaccine effectiveness against medically attended COVID-19 amongst individuals in clinical risk groups using cohort and test-negative case control designs. Findings There was no reduction in S-antibody positivity in most clinical risk groups, however reduced S-antibody positivity and response was significant in the immunosuppressed group. Reduced vaccine effectiveness against clinical disease was also noted in the immunosuppressed group; after a second dose, effectiveness was moderate (Pfizer 59.6%, 95%CI 18.0-80.1%; AstraZeneca 60.0%, 95%CI -63.6-90.2%). Interpretation In most clinical risk groups, immune response to primary vaccination was maintained and high levels of vaccine effectiveness were seen. Reduced antibody response and vaccine effectiveness were seen after 1 dose of vaccine amongst a broad immunosuppressed group, and second dose vaccine effectiveness was moderate. These findings support maximising coverage in immunosuppressed individuals and the policy of prioritisation of this group for third doses.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Etiology study / Observational study / Randomized controlled trials / Risk factors Language: English Year: 2022 Document Type: Article Affiliation country: J.jinf.2021.12.044

Full text: Available Collection: International databases Database: MEDLINE Type of study: Etiology study / Observational study / Randomized controlled trials / Risk factors Language: English Year: 2022 Document Type: Article Affiliation country: J.jinf.2021.12.044